Cambridge Investment Research Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Cambridge Investment Research Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,448	Closed	-$33K	–	2508
2019 Q4	$33K	Buy	+1,448	New	+$20.7K	﹤0.01%	2369
2019 Q1	–	Sell	-1,213	Closed	-$17K	–	2358
2018 Q4	$17K	Sell	1,213 -596	-33%	-$10.5K	﹤0.01%	2127
2018 Q3	$39K	Hold	1,809	–	–	﹤0.01%	2204
2018 Q2	$77K	Buy	1,809 +548	+43%	+$25.1K	﹤0.01%	2130
2018 Q1	$82K	Buy	+1,261	New	+$89.3K	﹤0.01%	2070

Other funds holding LUMO

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

IFG

Investors Financial Group Plymouth, Minnesota $215M AUM 19.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cambridge Investment Research Advisors's LUMO Position: Q1 2020 in Review

Cambridge Investment Research Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2020, closing a stake of 1,448 shares — an estimated $33K sold.

Cambridge Investment Research Advisors first reported a position in LUMO in Q1 2018 and held it in 5 quarters. The position peaked at $82K in Q1 2018. 46 funds tracked by Wall St. Rank hold LUMO as of Q1 2020.

Cambridge Investment Research Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Cambridge Investment Research Advisors sold 1,448 Lumos Pharma, Inc. Common Stock shares in Q1 2020, an estimated $33K.
Cambridge Investment Research Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
Cambridge Investment Research Advisors's Lumos Pharma, Inc. Common Stock position peaked at $82K in Q1 2018.
46 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2020.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2020, filed 8 May 2020.